Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)
Reinisch M, Blohmer JU, Link T, Just M, Untch M, Stoetzer O, Fasching P, Schneeweiss A, Wimberger P, Seiler S, Huober J, Thill M, Jackisch C, Rhiem K, Solbach C, Hanusch C, Denkert C, Engels K, Nekljudova V, Loibl S (2022)
Publication Type: Conference contribution
Publication year: 2022
Journal
Publisher: ELSEVIER
City/Town: AMSTERDAM
Pages Range: S166-S167
Conference Proceedings Title: ANNALS OF ONCOLOGY
DOI: 10.1016/j.annonc.2022.03.110
Authors with CRIS profile
Involved external institutions
Kliniken Essen-Mitte
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Technische Universität Dresden
Germany (DE)
Onkologische Schwerpunktpraxis Bielefeld
Germany (DE)
HELIOS Kliniken
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
Kantonsspital St.Gallen
Switzerland (CH)
Agaplesion Markus Krankenhaus
Germany (DE)
Sana Klinikum Offenbach
Germany (DE)
Universität zu Köln
Germany (DE)
Universitätsklinikum Frankfurt am Main (KGU)
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Philipps-Universität Marburg
Germany (DE)
Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss
Germany (DE)
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Technische Universität Dresden
Germany (DE)
Onkologische Schwerpunktpraxis Bielefeld
Germany (DE)
HELIOS Kliniken
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
Kantonsspital St.Gallen
Switzerland (CH)
Agaplesion Markus Krankenhaus
Germany (DE)
Sana Klinikum Offenbach
Germany (DE)
Universität zu Köln
Germany (DE)
Universitätsklinikum Frankfurt am Main (KGU)
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Philipps-Universität Marburg
Germany (DE)
Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss
Germany (DE)
How to cite
APA:
Reinisch, M., Blohmer, J.-U., Link, T., Just, M., Untch, M., Stoetzer, O.,... Loibl, S. (2022). Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC). In ANNALS OF ONCOLOGY (pp. S166-S167). AMSTERDAM: ELSEVIER.
MLA:
Reinisch, M., et al. "Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2022. S166-S167.
BibTeX: Download